Moderna's imminent FDA vaccine decision, TCGX launches $400M Asia biotech fund, and more biotech news
Moderna's FDA decision on mRNA flu vaccine nears as TCGX launches $400M Asia biotech fund. Pricing and rebate disputes tighten regulatory pressure, constraining pharma margins and reshaping biotech investment outlook.
Moderna’s imminent FDA vaccine decision, TCGX launches $400M Asia biotech fund, and more biotech news
HECTOR RETAMAL/AFP via Getty Images
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hiya, and welcome back to The Readout.
Today, we’re getting ready for the FDA’s upcoming decision on Moderna’s mRNA flu shot, and see both a revived fight over 340B rebates and fresh legal scrutiny for Lilly’s insulin pricing.
Moderna still bullish on mRNA, Ipsen's acquisition of Kartos, and more biotech news from The Readout
UniQure will submit Huntington's therapy for approval, Eli Lilly buys 4E Therapeutics, and more biotech news
AstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The…
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
AbbVie buys Apogee Therapeutics, LSD therapy Phase 3 results, and more biotech news from The Readout
Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The…
